Bristol-Myers Squibb Co (BUE:BMY) Other Financing: ARS-175,942 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:BMY Bristol-Myers Squibb Co BUE:BMY
56 GF Score
Price ARS30,980.00
GF Value ARS28,025.90
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Other Financing?

Bristol-Myers Squibb Co BUE:BMY +3.06% 56 Other Financing is ARS-175,942 Mil as of Mar. 2026. GuruFocus rates BUE:BMY with a GF Score™ of 56/100 and a GF Value™ of ARS28,025.90 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Bristol-Myers Squibb Co's Other Financing for the three months ended in Mar. 2026 was ARS-137,028 Mil.

Bristol-Myers Squibb Co's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was ARS-175,942 Mil.

Bristol-Myers Squibb Co Other Financing Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Other Financing Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64,734.59 164,967.60 9,747.00 -107,060.00 -185,790.59

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -109,801.81 13,059.57 -4,074.04 -47,899.14 -137,028.02
BUE:BMY
56GF Score
Bristol-Myers Squibb Co BUE:BMY
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-175,942 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ARS-175,942 Mil mean?
Bristol-Myers Squibb Co (BUE:BMY) has a Other Financing of ARS-175,942 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Other Financing too high?
Bristol-Myers Squibb Co's current Other Financing is ARS-175,942 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Other Financing compare to PFE and GILD?
Bristol-Myers Squibb Co's Other Financing of ARS-175,942 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Other Financing is ARS-175,942 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BUE:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS28,025.90, compared to a current price of ARS30,980.00 — trading 10.5% above its estimated fair value. The current Other Financing is ARS-175,942 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BUE:BMY), the current Other Financing is ARS-175,942 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (BUE:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of ARS30,980.00 is trading 10.5% above its estimated GF Value™ of ARS28,025.90. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for BUE:BMY:

  • Other Financing: ARS-175,942 Mil
  • GF Value™: ARS28,025.90 vs. price of ARS30,980.00 (10.5% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the BUE:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
56GF Score

Get the complete analysis for BUE:BMY

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS30,980.00
Price
ARS28,025.90
GF Value